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Objectives We hypothesized that cholesterol content is increased in the circulating erythrocytes of patients with acute coro-
nary syndrome (ACS) and may be a marker of clinical instability. We therefore sought to investigate whether
cholesterol content differs in erythrocyte membranes of patients presenting with ACS compared to patients with
chronic stable angina (CSA).
Background Plaque rupture in ACS depends at least partly on the volume of the necrotic lipid core. Histopathologic studies
have suggested that cholesterol transported by erythrocytes and deposited into the necrotic core of atheroma-
tous plaques contributes to lipid core growth.
Methods Consecutive angina patients were prospectively assessed; 120 had CSA (83 men, age 64  11 years) and 92
ACS (67 men, 66  11 years). Total cholesterol content in erythrocyte membranes (CEM) was measured using
an enzymatic assay, and protein content was assessed by the Bradford method.
Results The CEM (median and interquartile range) was higher (p  0.001) in ACS patients (184 g/mg; range 130.4 to
260.4 g/mg) compared with CSA patients (81.1 g/mg; range 53.9 to 109.1 g/mg) (analysis of covariance).
Total plasma cholesterol concentrations did not correlate with CEM levels (r  0.046, p  0.628).
Conclusions This study shows, for the first time, that CEM is significantly higher in patients with ACS compared with CSA pa-
tients. These findings suggest a potential role of CEM as a marker of atheromatous plaque growth and vulnera-
bility. Large ad hoc studies are required to establish the clinical importance and pathogenic significance of CEM
measurement. (J Am Coll Cardiol 2007;49:2081–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.069c
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ahe disruption of the fibrous cap of vulnerable coronary
theromatous plaques leads to intracoronary thrombosis and
he acute coronary syndrome (ACS) (i.e., myocardial infarc-
ion, unstable angina, and sudden cardiac death) (1,2).
therosclerotic plaque vulnerability to rupture depends on a
umber of factors that include the size of the necrotic lipid
rom the *Cardiovascular Biology Research Centre, Division of Cardiac and Vascular
ciences, St. George’s, University of London, London, United Kingdom; †Analytical
nit, Division of Cardiac and Vascular Sciences, St. George’s, University of London,
ondon, United Kingdom; and ‡University Cardiology Department, Democritus
niversity of Thrace, Alexandroupolis, Greece. Drs. Tziakas and Chalikias are
urrently affiliated with the Cardiology Department, Democritus University of
hrace, Alexandroupolis, Greece. Dr. Romero is currently affiliated with the Lipid
aboratory, Clinical Chemistry Department, Gregorio Marañón University Hospital,
adrid, Spain.u
Manuscript received March 14, 2006; revised manuscript received August 14, 2006,
ccepted August 21, 2006.ore, the presence of a thin fibrous cap, fewer smooth-
uscle cells, and the accumulation of activated macrophages
n the cap shoulder (1,2). Of importance, the size of the
theromatous core seems critical for the stability of the
laque (3,4). Davies et al. (5) showed that cap rupture is
ore likely to occur when the lipid core occupies 40% of
he atherosclerotic lesion area (4).
See page 2090
Aggregation of lipoproteins and their phagocytosis or
ndocytosis by macrophages contribute to the accumulation
f cholesterol within plaques (6) and thus to the growth of
he lipid core. However, although apoptotic macrophages
re an important source of cholesterol within plaques, it is
nlikely that all of the cholesterol contained in plaques
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Most of the cholesterol in foam
cell is esterified (7), whereas the
atherosclerotic lipid core has a
remarkably high content of free
cholesterol (6).
Arbustini et al. (8), in patients
with chronic thromboembolic
pulmonary hypertension, and
Kolodgie et al. (9), in patients
who died suddenly of coronary
causes, observed that advanced
atherosclerotic plaques contained
erythrocyte membranes in the
necrotic core, suggesting that red
blood cells may actively contrib-
ute to plaque growth. It has been
shown that the content of free
cholesterol in erythrocyte mem-
branes exceeds that of all other
cells in the body, with lipids con-
stituting 40% of their total
weight (10). Furthermore, recent
studies from Kolodgie et al. (9),
Purushothaman et al. (11), and
oreno et al. (12) have shown that angiogenesis and
ntraplaque hemorrhage are important in the development
f the vulnerable unstable atherosclerotic plaque.
It has been suggested that cholesterol contained in red
lood cell membranes participates in the rapid progression
f the atheromatous core and may lead to atheromatous
laque instability. The contribution of cholesterol content
f erythrocyte membranes to the clinical presentation of
oronary artery disease (CAD) and the rapid progression of
oronary atheroma has not been studied. We therefore
ought to assess whether total cholesterol content of eryth-
ocyte membranes (CEM) differs between patients with
table and those with unstable CAD and may thus represent
oth a marker of plaque vulnerability and a pathogenic
echanism of ACS in CAD patients.
ethods
atients. We prospectively recruited 212 consecutive pa-
ients admitted to our institution for the assessment of
ngina pectoris. Of these, 120 had stable CAD and 92
CS; of the latter, 50 had ST-segment elevation myocardial
nfarction, 27 non–ST-segment elevation myocardial infarc-
ion, and 15 unstable angina. In addition, we assessed 65
ndividuals (41 men, age 63  13 years) with atypical chest
ain and normal coronary arteries on angiography who were
onsidered to represent a control group.
Stable CAD was defined as typical exertional chest pain
elieved by rest and/or nitrates, without a change in fre-
uency or pattern for 3 months before study entry, and with
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CEM  total cholesterol
content of erythrocyte
membranes
CI  confidence interval
CRP  C-reactive protein
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
OR  odds ratio
RBC  red blood cell
ROC  receiver-operating
characteristics curvepositive response (1 mm ST-segment depression) to axercise stress testing. Myocardial infarction was diagnosed
n the presence of prolonged (20 min) chest pain, with
T-segment changes suggestive of myocardial ischemia or
ecrosis on the standard 12-lead electrocardiogram, associ-
ted with increased serum markers of myocardial damage
easured on at least two occasions during the first 24 h after
he index event (2-fold increase over the upper normal
ange required for creatine kinase-myocardial fraction and
roponin T). Myocardial infarction patients were considered
o have ST-segment elevation myocardial infarction in the
resence of0.2 mV ST-segment elevation at the J point in
or more contiguous electrocardiogram leads. We diag-
osed non–ST-segment elevation myocardial infarction in
he presence of new ST-segment depression (0.1 mV)
nd/or T-wave inversion (0.3 mV) in two or more contigu-
us leads (13,14). Unstable angina was defined as anginal pain
t rest fulfilling Braunwald’s IIIb criteria with transient signif-
cant ischemic ST-segment or T-wave changes, or both,
ithout evidence of myocardial damage (15).
The present study did not include patients with a history
f a previous ACS; excessive alcohol intake; hematologic,
enal, liver, or thyroid diseases; or malignancies. Further-
ore, patients with infectious or autoimmune diseases,
amilial hyperlipidemia, and those undergoing surgical pro-
edures in the preceding 3 months were excluded from the
tudy. None of the patients in the study was receiving
reatment with anti-inflammatory drugs or hormone re-
lacement therapy. We also excluded patients with abnor-
al red blood cell (RBC) counts (4.7 and 5.9  106/l
or men and 4.2 and 5.4  106/l for women) and/or
bnormal hemoglobin levels (13.5 g/dl and 18 g/dl for
en and 12.5 g/dl and 16 g/dl for women). The study
as approved by the local research ethics committee, and all
atients gave written informed consent before study entry.
The patients’ baseline clinical characteristics at initial
resentation are summarized in Table 1.
ngiographic analysis. In all of the patients, coronary
ngiography was carried out according to the Judkins
echnique, and images of the coronary tree were obtained in
outine, standardized projections with the digital Philips
ntegris 3000 System (Philips Medical Systems Interna-
ional, Best, the Netherlands). Two experienced cardiolo-
ists who had no knowledge of the patients’ clinical char-
cteristics and biochemical results visually reviewed all
ngiographic images to assess the extent and severity of
AD. Vessel score was used to assess the extent of the
therosclerotic disease in the coronary artery tree. Vessel
core is based on the number of diseased coronary arteries,
here a coronary artery is regarded as “diseased” in the
resence of 75% reduction in lumen diameter (14).
tenosis score was used to assess the severity of CAD on
ngiography. Stenosis score, as described in previous studies
rom our group (16), is aimed at reflecting the most severe
tenosis observed in each of the main coronary vessels
ssessed. Interobserver variability for vessel score was 3.8%.
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May 29, 2007:2081–9 Erythrocytes and Coronary Disease Instabilityaboratory analysis. In every patient, peripheral blood
amples for CEM and other biochemical variables were
btained after a 12-h overnight fast, at the time of coronary
ngiography immediately after the catheterization of the
emoral artery, and before the infusion of heparin and
ngiographic contrast medium. Blood specimens for CEM
nalysis were collected in standard vacutainer tubes contain-
ng citrate. A 3-ml aliquot of venous blood collected in
itrate plasma tubes was centrifuged at 1,500 rpm for 10
in at 4°C; the plasma and buffy coat were carefully
emoved by aspiration, and the remaining RBCs were
Demographic and Clinical Data in Patients With
Table 1 Demographic and Clinical Data in P
Stable C
Men/women, n 8
Age, yrs 6
BMI, kg/m2 2
Erythrocyte count, 106/l 5 (
Hemoglobin, g/dl 15.1 (
History of ACS, n (%)
History of coronary intervention
CABG, n (%) 8 (
PCI, n (%) 8 (
Risk factors
Diabetes mellitus, n (%) 29 (
Hypertension, n (%) 75 (
Smoking, n (%) 26 (
Family history, n (%) 75 (
Dyslipidemia, n (%) 91 (
Medications
Nitrates, n (%) 26 (
Beta-blockers, n (%) 72 (
Calcium antagonists, n (%) 65 (
Aspirin, n (%) 96 (
Statins, n (%) 78 (
ACE inhibitors, n (%) 51 (
Clopidogrel, n (%) 8 (
Fibrates, n (%) 2 (
Ezetimibe, n (%) 1 (
Omega-3 marine triglycerides, n (%) 1 (
Angiographic analysis
Nonsignificant disease 15 (
1-vessel disease 34 (
2-vessel disease 32 (
3-vessel disease 39 (
LMS disease 18 (
Biochemistry
Creatinine, mmol/l 87 (
Total cholesterol, mmol/l 4.9 (
LDL cholesterol, mmol/l 2.9 (
HDL cholesterol, mmol/l 1.2 (
Triglycerides, mmol/l 1.5 (
CRP, mg/l 2.7 (
Values are expressed as median SD or median and interquartile ran
variables. *For chi-square test; †for Mann-Whitney U test.
ACE  angiotensin-converting enzyme; ACS  acute coronary syndr
coronary artery disease; CRP  C-reactive protein; HDL  high-densi
percutaneous coronary intervention.esuspended and washed twice in 154 mM NaCl isotonic polution (17). One milliliter of washed erythrocytes solution
as hypotonically lysed in 30 volumes of cold distilled
ater, mixed by vortex, and allowed to stand for 15 min.
embranes were separated from the hemolysate (superna-
ant from hemolyzed RBCs) by centrifugation at 15,000
pm for 15 min at 4°C, this step was repeated 3 times until
white/pale pink pellet containing hemoglobin-free eryth-
ocytes (ghosts) was obtained (18).
Erythrocyte ghosts were resuspended in 1 ml of PBS and
tored at 20°C until further analysis. A 125 l aliquot of
embrane suspension was used to determine membrane
le CAD and Subjects With ACS
ts With Stable CAD and Subjects With ACS
 120) ACS (n  92) p Value
67/25 0.648
66  11 0.314
27  4 0.324
3) 5.1 (4.7–5.3) 0.618
6.2) 14.9 (13.8–16.3) 0.819
—
0.005*
—
2 (2%)
17 (19%) 0.401
63 (68%) 0.386
23 (25%) 0.623
28 (30%) 0.001*
48 (52%) 0.001*
14 (15%) 0.289
14 (15%) 0.001*
45 (49%) 0.448
26 (28%) 0.001*
22 (24%) 0.001*
16 (17%) 0.001*
4 (4%) 0.559
1 (1%) 1
— 1
— 1
0.527
6 (7%)
26 (28%)
26 (28%)
34 (37%)
17 (18%) 0.557
4) 91 (79–109) 0.157
7) 4.5 (4–5.5) 0.091
6) 2.8 (2.3–3.5) 0.640
1 (0.9–1.2) 0.001†
1.5 (1.1–2.1) 0.915
8.8 (3.9–14.5) 0.001†
ontinuous variables, and as number of patients and % for categorical
MI  body mass index; CABG  coronary artery bypass graft; CAD 
rotein; LDL  low-density lipoprotein; LMS  left main stem; PCI Stab
atien
AD (n
3/37
4  11
7  5
4.7–5.
14.1–1
—
7%)
7%)
24%)
63%)
22%)
62%)
76%)
22%)
60%)
54%)
80%)
65%)
42%)
7%)
2%)
1%)
1%)
12%)
28%)
27%)
33%)
15%)
74–10
4.1–5.
2.2–3.
1–1.4)
1–2)
1–5.7)
ge for c
ome; Brotein concentration by the method of Bradford using
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Erythrocytes and Coronary Disease Instability May 29, 2007:2081–9ovine serum albumin as a standard (19). Red blood cell
embrane lipid extraction was carried out from a second
00 l aliquot following Folch’s method (20).
Total cholesterol was measured on RBC membrane lipid
xtracts by means of a commercial enzymatic assay (Waco
hemicals GmbH, Neuss, Germany) (21) following the
nstructions of the manufacturer. The detection limit of the
ssay was 1.8 mg/dl, and the manufacturer’s reported intra-
nd interassay precision were both1.1%. Briefly, a 6-point
alibration curve was prepared by diluting the standard
olution provided in the kit, the absorbance of each sample
as measured against blank at 505 nm and the result was
lotted against the calibration curve to obtain the amount of
otal cholesterol. All the samples were measured in dupli-
ates and none of the duplicates had a coefficient of variation
igher than 4%. We were able to measure the amount of
holesterol in all the samples assayed. Results are expressed
s micrograms of total membrane cholesterol per milligram
f membrane protein.
C-reactive protein (CRP) was measured on the COBAS
ntegra (Roche Diagnostics Limited, Lewes, East Sussex,
nited Kingdom) using the CRP latex assay in both the
igh-sensitivity application (analytical range 0.2 to 12 mg/l)
nd the normal application (analytical range 2 to 160 mg/l).
ll other biochemistry measurements were carried out using
tandard methods.
tatistical analysis. Results for continuous variables are
resented as means and SD or as medians and interquartile
anges if the distributions were skewed and as percentages
or categorical data. The 2-tailed unpaired Student t test or
he Mann-Whitney U test were used to evaluate differences
n continuous variables between the 2 groups. Comparisons
etween categorical variables were performed with the
hi-square test or Fisher exact test as appropriate. Normality
as tested using the Kolmogorov-Smirnov test. The CEM,
RP, creatinine, triglycerides, total cholesterol, low-density
ipoprotein (LDL) cholesterol, and high-density lipoprotein
HDL) cholesterol levels were not normally distributed and
ere therefore logarithmically transformed as required to
pproach normal distribution and obtain equal variances.
nalysis of variance with covariates (ANCOVA) was used
o evaluate differences in CEM levels between stable CAD
nd ACS patients after adjustment for all the variables that
ere significantly different between the two patient groups.
Because preliminary analysis suggested that association
etween CEM levels and CAD instability was more of a
hreshold effect, CEM levels were assessed as a dichoto-
ous variable using its median value as a cutoff point.
imilarly, continuous variables with skewed distribution
ere also assessed as dichotomous variables using as cutoff
oints their risk-associated levels in CAD patients (i.e.,
otal cholesterol 4.5 mmol/l; LDL 2.5 mmol/l, and HDL
holesterol 1.1 mmol/l; triglycerides 1.7 mmol/l; CRP 3
g/l, and creatinine 107 mmol/l) (22).
Simple logistic regression analysis was used to assessnivariate associations between patients’ characteristics and aiochemical measurements and CAD status (stable CAD
s. ACS). Multiple logistic regression analysis was used to
ssess the independent adjusted relationship between CEM
evels and CAD status, with independent variables being
hose with p  0.05 on univariate analysis. Odds ratios
OR) with 95% confidence intervals (CI) were calculated for
ll patients (n  212, stable CAD and ACS). The OR for
ichotomized continuous variables represents the relative
isk between levels above and below the prespecified cutoff
oint. The OR for categorical variables represents the
elative risk between the presence or absence of the variable.
orrelation analysis between variables was carried out by
pearman’s correlation coefficient (r). Receiver-operating
haracteristic (ROC) curves were calculated for CEM,
/HDL, and CRP levels. A p value 0.05 was considered
o indicate statistical significance. The SPSS 11.0 statistical
oftware package (SPSS Inc., Chicago, Illinois) was used for
ll calculations.
esults
aseline characteristics. Baseline characteristics of pa-
ients with stable CAD and ACS are presented in Table 1.
higher proportion of stable CAD patients had a history of
revious coronary intervention (i.e., coronary artery bypass
raft or percutaneous coronary intervention). Established
isk factors for CAD were similar in the 2 groups, with the
xception of family history of CAD and dyslipidemia, which
ere more common in stable CAD patients than in ACS
atients. The medications taken by both groups at study
ntry were similar, with the exception of beta-blockers,
tatins, angiotensin-converting enzyme (ACE) inhibitors,
nd aspirin, which, as expected, were significantly more
ommon in the stable CAD group. Angiographically based
AD was similar in the 2 groups. Total cholesterol,
riglyceride, and LDL cholesterol levels did not differ
ignificantly between the two groups. However, HDL
holesterol levels were higher in the stable CAD group, and
RP levels were significantly higher in ACS patients.
otal cholesterol content of erythrocyte membranes.
he CEM was significantly higher (p  0.001) in the
nstable CAD patient group (184 g/mg, range 130.4 to
60.4 g/mg) compared with patients with stable CAD
81.1 g/mg, range 53.9 to 109.1 g/mg) (Fig. 1). Analysis
f covariance showed that CEM remained significantly
igher (p  0.001) in the unstable CAD group after
djustment for all the variables that were significantly
ifferent between the 2 groups (R2  0.437; for full model
 0.001). In detail, estimated covariate-adjusted means
ith 95% CIs for CEM levels among the 2 study groups
ssessed with the ANCOVA model were 80 g/mg 95% CI
1.9 to 89.1 for CSA patients and 181.1 g/mg 95% CI
59.6 to 206.1 for ACS patients.
As cholesterol load in erythrocyte membranes has not
een extensively assessed in the general population, we
ssessed CEM levels in an age- (p  0.457) and gender-
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May 29, 2007:2081–9 Erythrocytes and Coronary Disease Instabilityp  0.428) matched group of individuals with normal
oronary arteries as a mean of comparison. Mann-Whitney
test showed that CEM values were higher (p  0.001) in
nstable CAD patients compared to individuals without
ngiographic CAD (63.8 g/mg, range 43.3 to 91.3 g/
g). In contrast, CEM did not differ in the control group
ompared with stable CAD patients (p  0.08).
The proportion of patients with ACS across CEM
eciles (Fig. 2) shows that the association between CEM
nd CAD status appears to be more of a threshold effect. In
iew of this finding, we used the median CEM level (112.1
g/mg) as a cutpoint and conducted evaluations for evi-
ence of association between CEM and CAD status (stable
s. ACS) above and below the aforementioned cutoff value.
Table 2 summarizes results of simple logistic regression
nalysis for each of the patients’ clinical variables considered
nd biochemical measurements that could be a reflection of
AD activity. Increased CEM measurements were predic-
ive of ACS, as were CRP levels, whereas high HDL
holesterol levels were a negative predictor. Statin, ACE
nhibitor, beta-blocker, and aspirin use were negatively
ssociated with ACS. Similarly, family history of CAD,
yslipidemia, and history of coronary intervention were also
egative predictors.
After adjustment for all the variables that were associated
ith CAD activity on univariate analysis (family history of
AD, dyslipidemia, history of coronary intervention, stat-
ns, ACE inhibitors, beta-blockers, aspirin, CRP levels, and
DL levels), multiple logistic regression analysis showed
hat high CEM levels continued to have an independent
Figure 1 Total Cholesterol Content of Erythrocyte
Membranes in Stable CAD and ACS Patients
Box plots represent median, quartiles, and range values of total cholesterol
content of erythrocyte membranes (CEM). Data do not reflect logarithmic trans-
formation or covariate adjustment as assessed in the analysis of covariance
model. ACS  acute coronary syndrome; CAD  coronary artery disease.ignificant association with ACS (Table 3). rorrelation and subgroup analysis. Correlation analysis
howed no linear association between CEM and serum total
holesterol concentration (r  0.046; p  0.628), LDL
r  0.042; p  0.654) or HDL cholesterol levels (r 
0.140; p  0.136), and triglyceride levels (r  0.114;
 0.224) in the whole patient group. As the possibility
hat statin use could influence the association observed
Figure 2 Number of Patients With
ACS in Each Decile of CEM
Deciles d1 through d10 correspond to the following values: 47.6 g/mg,
47.6 to 60.7 g/mg, 60.7 to 82 g/mg, 82 to 103.6 g/mg, 103.6 to
112.1 g/mg, 112.1 to 132.4 g/mg, 132.4 to 173.1 g/mg, 173.1 to
212.6 g/mg, 212.6 to 284.8 g/mg, and 284.8 g/mg, respectively.
Bars represent number of ACS patients within each decile. Abbreviations as in
Figure 1.
esults of Univariable Logistic Regression Analysisgarding CAD Status (Stable CAD v . ACS) inhole Patie t G oup (n  212)
Table 2
Results of Univariable Logistic Regression Analysis
Regarding CAD Status (Stable CAD vs. ACS) in
Whole Patient Group (n  212)
Variable OR 95% CI p Value
CEM (cutpoint 112.1 g/mg) 32.8 14.8–72.6 0.001
CRP (cutpoint 3 mg/l) 4.91 2.57–9.38 0.001
HDL cholesterol (cutpoint 1.1 mmol/l) 0.21 0.12–0.38 0.001
Dyslipidemia 0.35 0.19–0.62 0.001
Family history 0.26 0.15–0.47 0.001
History of coronary intervention 0.14 0.03–0.65 0.011
Statin 0.17 0.09–0.31 0.001
ACE inhibitor 0.28 0.15–0.54 0.001
Beta-blocker 0.12 0.06–0.23 0.001
Aspirin 0.10 0.05–0.18 0.001
Rs for dichotomized continuous variables represent the relative risk calculated by comparing low
ersus high levels using an arbitrary cutpoint. Odds ratios for categorical variables represent the
elative risk between the presence or absence of the variable. Total cholesterol (p  0.079), LDL
holesterol (p 0.221), triglycerides (p 0.126), creatinine (p 0.453), age (p 0.313), gender
p  0.562), BMI (p  0.323), diabetes mellitus (p  0.321), hypertension (p  0.366), smoking
p  0.569), nitrate (p  0.236), calcium channel blocker (p  0.371), clopidogrel (p  0.472),
brate (p  0.771), number of diseased coronary vessels (for 1 vessel disease, p  0.238; for
-vessel disease, p  0.198; for 3-vessel disease, p  0.147), and presence of LMS (p  0.500)
ere not significant predictors.
CI confidence interval; CEM total cholesterol content of erythrocyte membranes; OR odds
atio; other abbreviations as in Table 1.
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Erythrocytes and Coronary Disease Instability May 29, 2007:2081–9etween CEM and lipid levels could not be excluded, we
epeated the linear correlation analysis in a subgroup of
atients who were not receiving statin treatment (n  112).
e found that there was no linear association between
EM and serum total cholesterol (r 0.211; p 0.129),
DL (r  0.212; p  0.128) and HDL cholesterol levels
r  0.166; p  0.236). Furthermore, there was no
ssociation between CEM levels and body mass index (r 
.068; p 0.322). Moreover, we did not observe significant
ifferences (p  0.445) in CEM levels between male (n 
50, 117.7 g/mg (interquartile range 63.1 to 184 g/mg)
nd female (n  62, 108.3 g/mg (interquartile range 77.9
o 244.9 g/mg) patients when the whole patient group was
onsidered.
In addition, high CEM levels were associated with ACS
tatus both in a subgroup of patients with high total
holesterol levels (n  125, 4.5 mmol/l) (OR 35.54, 95%
I 12.02 to 105.2; p 0.001) and in a subgroup of patients
ith low cholesterol levels (n  87, 4.5 mmol/l) (OR
9.47, 95% CI 9 to 96.47, p  0.001).
The use of statins was associated with lower CEM values
n  100, 84.8 g/mg, range 53.9 to 135.7 g/mg) (p 
.001) compared with patients not receiving lipid-lowering
reatments (n  112, 147.2 g/mg, range 106.6 to 212.6
g/mg). In view of the association observed between statin
se and CEM levels, we compared the predictive ability of
EM in both ACS patients with and without statin
reatment. In the subgroup of patients receiving statin
reatment, CEM levels were predictive of ACS (OR low vs.
igh 30.6, 95% CI 8.59 to 109, p  0.001). Furthermore,
EM levels were also associated with ACS (OR low vs.
igh 21.33, 95% CI 7.43 to 61.22, p  0.001) in the
ubgroup of patients not receiving statin treatment.
As disrupted or ulcerated atherosclerotic plaques are
ssociated with ACS (23) and rapid disease progression
24), and often appear as “complex” stenoses at angiography,
e assessed lesion morphology in all stenoses with 75%
iameter reduction. Briefly, stenoses were subdivided into
omplex or smooth, as reported in previous studies by our
esults of Multivariable Logistic Regressionnalysis Regarding CAD Status (Stabl CAD vs.CS) in Whole Patient Gr up (n  212)
Table 3
Results of Multivariable Logistic Regression
Analysis Regarding CAD Status (Stable CAD vs.
ACS) in Whole Patient Group (n  212)
Variable OR 95% CI p Value
CEM (cutpoint 112.1 g/mg) 25.98 8.77–76.96 0.001
CRP (cutpoint 3 mg/l) 2.97 0.97–9.20 0.058
HDL cholesterol (cutpoint 1.1 mmol/l) 0.17 0.05–0.50 0.001
Beta-blocker 0.30 0.10–0.91 0.034
Aspirin 0.12 0.04–0.39 0.001
dds ratios for dichotomized continuous variables represent the relative risk calculated by
omparing low versus high levels using an arbitrary cutpoint. ORs for categorical variables
epresent the relative risk between the presence or absence of the variable. Multivariable adjusted
nalysis controlled for CRP levels, HDL cholesterol levels, beta-blocker use, aspirin use, statin use,
CE inhibitor use, dyslipidemia, history of coronary intervention, and family history of CAD. Family
istory of CAD (p 0.073), dyslipidemia (p 0.078), history of coronary intervention (p 0.734),
tatin use (p  0.094), and ACE inhibitor use (p  0.093) were not significant predictors.
Abbreviations as in Tables 1 and 2.roup and others (23,24), and the presence or absence ofomplex angiographic lesion morphology was correlated
ith CEM results. We observed that the presence of
ngiographically complex coronary lesions was associated
ith a significantly (p 0.027) higher CEM (110.5 g/mg,
ange 71 to 183.7 g/mg) compared to absence of such
orphology in coronary angiography (92.9 g/mg, range
3.9 to 111.5 g/mg). Furthermore, CEM levels were also
ignificantly positively correlated with the number of com-
lex lesions (r  0.272; p  0.003). However, CEM levels
ere not correlated with number of diseased vessels (r 
0.080, p  0.246) or with stenosis score (r  0.024, p 
.730) observed on coronary angiography.
OC analysis. Consistent with these results, ROC analy-
is regarding predictive accuracy for patients’ CAD status
howed that for CEM, the area under the curve was 0.885
0.840 to 0.931); p  0.001, for CRP 0.737 (0.669 to
.806); p  0.001, and for 1/HDL cholesterol 0.711 (0.640
o 0.781); p  0.001. Receiver-operating characteristics
nalysis, albeit not controlling for possible confounders,
ndicates that CEM was a better marker of CAD activity
han either CRP or HDL cholesterol levels (Fig. 3).
iscussion
ur study showed for the first time that CEM values are
igher in patients with ACS than in stable CAD patients.
holesterol content of erythrocyte membranes was a marker
or CAD activity, and we observed a strong association
etween CEM and ACS, which was independent of other
Figure 3 ROC Analysis Regarding Predictive
Accuracy for the Characterization of CAD Activity
The bold line represents receiver-operating characteristic curve (ROC) analysis
for total cholesterol content of erythrocyte membranes. The continuous line
represents ROC analysis for C-reactive protein (CRP) levels. The dotted line
represents ROC analysis for 1/high-density lipoprotein (HDL) cholesterol levels.
CAD  coronary artery disease.
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EM was a stronger predictor of ACS than established
arkers of CAD activity such as CRP (25) and HDL
holesterol (26,27). Our finding that CEM did not differ
etween stable CAD patients and individuals with normal
oronary arteries further supports the suggestion that in-
reased CEM is a marker of CAD instability and not of the
resence of atherosclerosis. A marker of CAD activity may
e useful in the clinical setting, as the often rapid transition
rom a subclinical or stable clinical condition to life-
hreatening ACS cannot be reliably predicted using tradi-
ional risk factors (28).
These observations are in keeping with the results of
istopathology studies suggesting that the instability of
therosclerotic plaques may be mediated at least in part by
rythrocyte membrane cholesterol (9) through an enlarge-
ent of the lipid core. Arbustini et al. (8) reported that
therosclerotic plaques outside the coronary circulation
ontain glycophorin, an exclusive component of erythrocyte
embranes (29). Consistent with the findings of Arbustini
t al. (8), Kolodgie et al. (9) found erythrocyte membranes
o be present in the necrotic core of advanced coronary
theroma. Moreover, they also showed that erythrocyte
embrane cholesterol contributes to an abrupt increase in
he content of cholesterol in the necrotic core of coronary
esions. Thus, taking these findings together, it is conceiv-
ble that CEM may contribute to the expansion of the
ecrotic core and, in turn, to plaque instability. Various
nvestigators (9,11,12,30) have reported that intraplaque
emorrhage and plaque neovascularization are associated
ith plaque vulnerability and the rupture of the fibrous cap
f atheromatous lesions.
Although in the present study we did not specifically
nvestigate plaque instability, our findings suggest a possible
ink between CEM levels and clinical instability, which
ay, in turn, reflect atheromatous plaque instability. This
ssue, however, requires further investigation. The potential
echanisms whereby erythrocyte membrane derived cho-
esterol can contribute to plaque instability are speculative at
resent but may include: 1) an abrupt expansion of the
ecrotic core (3–5); 2) a change in the lipid composition of
he atheromatous core favoring a predominance of free
holesterol (31,32); 3) inflammatory mechanisms, because
rythrocyte membranes can bind a wide array of chemokines
uch as interleukin-8 (33); 4) erythrophagocytosis that may
ead to foam cell formation and macrophage activation (34);
nd 5) a combination of these mechanisms.
Lipid contained in erythrocyte membranes results from
n exchange of lipoproteins between erythrocytes and the
irculation (35), as erythrocytes are not capable of synthe-
izing lipids de novo. In our study, however, circulating
holesterol levels did not correlate with CEM content,
robably because CEM content represents the equilibrium
chieved between red cell cholesterol influx and efflux, and
ntracellular cholesterol transport. Several enzymatic and
rotein-mediated pathways are involved in the handling of Cholesterol by the erythrocyte, which are regulated by
omplex feedback mechanisms and genetic factors that
egulate protein expression and enzymatic activity (36). In
ontrast to our results, studies (37,38) have reported an
ssociation between plasma cholesterol and CEM levels. An
xplanation of this disparity may be that the aforementioned
tudies showed that a reduction in plasma lipid levels was
ssociated with a similar reduction in CEM levels. How-
ver, none of the studies reported a direct correlation
etween CEM levels and plasma lipid concentrations as
ssessed by specific correlation statistical tests. The mecha-
isms responsible for increased CEM in patients with ACS
equire investigation. Increased cholesterol uptake by the
rythrocyte membrane, reduced cholesterol efflux, or both
ay be responsible. The relationship between CEM and
irculating cholesterol levels also deserves further investigation.
The CEM levels were lower in patients receiving treat-
ent with statins compared to patients without lipid-
owering treatment, suggesting that the exchange mecha-
isms responsible for cholesterol uptake and/or efflux by the
rythrocyte can be affected by statins. This is in agreement
ith previous studies that have reported that statin treat-
ent decreases cholesterol content of erythrocyte mem-
ranes in patients with hypercholesterolemia (37,38). Al-
hough the use of statins could beneficially affect erythrocyte
embrane lipids, the association between increased CEM
nd ACS in the present study was independent of lipid-
owering treatment. The intriguing finding in our study that
tatin use is associated with CEM levels, whereas choles-
erol levels are not, suggests that CEM levels are indepen-
ent of circulating cholesterol levels, and statin treatment
ay have an effect that does not necessarily parallel that on
holesterol plasma levels. Of importance, other studies (39)
eported that diet-induced reductions in circulating lipid
evels were not paralleled by reductions in CEM levels,
urther strengthening our hypothesis that the effect of statins
n CEM levels may be at least partially independent from the
eduction they cause in plasma cholesterol concentrations.
Although our study was not aimed at assessing the
ssociation between CEM levels and angiographic CAD,
e observed that CEM levels were associated with the
resence of angiographically complex coronary lesions, a
redictor of rapid disease progression and adverse prognosis
n established CAD patients (23,24). These results endorse
he hypothesis that increased levels of CEM may favor
laque instability and the development of ACS. Our finding
hat CEM levels were not associated with extent or severity
f CAD is in agreement with previous studies (40) that
uggested a lack of association between the extent and
everity of coronary stenosis and the risk of myocardial
nfarction and unstable angina.
In summary, the present study has shown for the first
ime a significant independent association between CEM in
irculating red cells and CAD clinical presentation. Our
esults are novel and intriguing and indicate not only that
EM may be a marker of clinical instability, but also a
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Erythrocytes and Coronary Disease Instability May 29, 2007:2081–9romoter of plaque instability and atheromatous core
rowth. The findings of the present study should be
nterpreted in light of certain limitations. First, our inves-
igation represents a small observational study; however, it
as powered enough to detect differences in CEM levels
mong study groups. Even with the relatively small sample
ize, the present study is hypothesis-generating. Larger
tudies are required to investigate further the predictive
alue of CEM. Second, underlying pathogenetic mecha-
isms are still speculative. Our results, together with the
vidence of presence of erythrocytes in ruptured atheroscle-
otic plaques documented in previous studies (8,9), have
mportant pathophysiologic implications, and the correla-
ion between CEM and the clinical presentation further
inks the erythrocytes with pathogenetic events. However, it
s not known how and by which mechanism erythrocytes
ecome loaded with cholesterol, or to what extent plaque
eovascularization and plaque positive remodeling contrib-
te to CEM-related risk. Finally, we did not determine
lood viscosity, a factor that could increase the risk of
schemia, especially in CAD patients (41). However, it is
nlikely that a difference existed in blood viscosity among
CS and CSA patients, as there were no differences in the
ajor determinants of blood viscosity (i.e., hemoglobin
evels and red blood cell count) between the 2 groups (42).
ifferences in CEM levels could not account for a signifi-
ant difference in viscosity because the impact of lipid
omposition of erythrocyte membranes on blood viscosity is
inimal (38). Furthermore, the clinical relevance of an
ssociation between these rheologic factors and the risk of
oronary heart disease remains unclear (43). Altered lipid
omposition of the erythrocyte membranes may affect plate-
et reactivity and thrombus formation and could represent a
athogenic link between CEM and ACS (44). However,
he clinical relevance of such a relationship requires inves-
igation (44). Nevertheless, our findings indicate that ACS
atients have raised CEM levels, and these levels cannot be
xplained simply by the presence of underlying risk factors,
linical features, and concurrent medications. Further stud-
es are warranted to elucidate the role of cholesterol con-
ained in RBC membranes as both a marker of plaque
nstability and a pathogenic mechanism of rapid CAD
rogression.
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